Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.
In This Article:
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.
Terms and Privacy Policy